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Abstract
The transcription factor Nrf2 is the master regulator of a cellular defense mechanism against environmental insults. The
Nrf2-mediated antioxidant response is accomplished by the transcription of a battery of genes that encode phase II
detoxifying enzymes, xenobiotic transporters, and antioxidants. Coordinated expression of these genes is critical in
protecting cells from toxic and carcinogenic insults and in maintaining cellular redox homeostasis. Activation of the Nrf2
pathway is primarily controlled by Kelch-like ECH-associated protein 1 (Keap1), which is a molecular switch that turns on or
off the Nrf2 signaling pathway according to intracellular redox conditions. Here we report our finding of a novel Nrf2
suppressor ectodermal-neural cortex 1 (ENC1), which is a BTB-Kelch protein and belongs to the same family as Keap1.
Transient expression of ENC1 reduced steady-state levels of Nrf2 and its downstream gene expression. Although ENC1
interacted with Keap1 indirectly, the ENC1-mediated down-regulation of Nrf2 was independent of Keap1. The negative
effect of ENC1 on Nrf2 was not due to a change in the stability of Nrf2 because neither proteasomal nor lysosomal inhibitors
had any effects. Overexpression of ENC1 did not result in a change in the level of Nrf2 mRNA, rather, it caused a decrease in
the rate of Nrf2 protein synthesis. These results demonstrate that ENC1 functions as a negative regulator of Nrf2 through
suppressing Nrf2 protein translation, which adds another level of complexity in controlling the Nrf2 signaling pathway.
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Introduction
A variety of environmental toxicants, such as natural toxins,
pollutants, heavy metals and chemical compounds, damage cells
by generating reactive oxygen species (ROS) and thus disrupt the
balance of cellular redox homeostasis [1,2]. Loss of cellular redox
homeostasis is regarded as oxidative stress, which elicits many
cellular antioxidant responses [1]. One of the most important
cellular antioxidant responses is regulated by Nrf2, a basic leucine
zipper transcription factor. Nrf2 protects cells from environmental
insults through transcriptional up-regulation of many antioxidant
response element (ARE)-bearing genes including, antioxidant-
encoding genes, phase II detoxifying genes, and phase III
transporter genes [3,4,5,6]. Coordinated induction of these genes
allows cells to effectively neutralize and remove detrimental ROS
to restore redox homeostasis and to avoid ROS-induced damage
on cellular macromolecules, such as DNA, lipids, and proteins
[5,7,8]. A growing body of evidence has associated ROS with the
pathogenesis of many human diseases, such as cancer, neurode-
generative disease, cardiovascular disease, aging and inflammation
[9,10,11,12,13]. Therefore, understanding how the Nrf2-depen-
dent antioxidant response is controlled is of great significance in
the development of novel strategies and chemopreventive drugs for
the prevention and treatment of diseases [8,12,14,15,16].
In the past decade, much progress has been made in the
understanding of the mechanisms by which the Nrf2 signaling
pathway is efficiently regulated in response to oxidative stress or
chemopreventive compounds such as sulforaphane (SF) [2,17,18].
The Neh2 domain, located at the amino terminus of Nrf2, is
responsible for binding the critical negative regulator of Nrf2,
Kelch-like ECH-associated protein 1 (Keap1) [2,19,20,21]. Seven
lysine residues in the Neh2 region have been shown to be essential
for accepting Keap1-dependent ubiquitination by the Keap1-
Cul3-Rbx1 E3 ubiquitin ligase complex, and is subsequently
degraded by 26S proteasome [19]. Keap1, initially identified by a
yeast two-hybrid system using Neh2 as a bait, is composed of five
domains: N-terminal region, Broad complex, Tamtrack and Bric a
brac domain (BTB), intervening region, Kelch, and C-terminal
region [22]. The BTB domain has been demonstrated to be
important for homodimerization of Keap1 and is also the region
for Cul3 binding [19,23]. The Kelch domain of Keap1 interacts
with the Neh2 domain of Nrf2 [22]. Under normal conditions, low
basal level of Nrf2 is achieved by constant degradation through the
Keap1-Cul3-Rbx1 dependent ubiquitination and proteasomal
degradation [2,18,24]. When cells are challenged by oxidative
stress or treated with chemopreventive compounds, Keap1 acts as
a stress sensor through its cysteine residues, in particular cysteine-
151. Modification of certain cysteine residues leads to a
conformational change of the E3 ubiquitin ligase, which
significantly impairs and attenuates enzymatic activities of the
E3 ligase. As a result, ubiquitination of Nrf2 and its degradation by
the 26S proteasome decline rapidly. Nrf2 proteins translocate into
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NAD(P)H quinone oxidoreductase (NQO1), glutathione S-trans-
ferase (GST), and heme oxygenase-1 (HO-1).
Regulation of gene expression is generally controlled at several
levels: (i) control of gene transcription, (ii) control of post-
transcriptional translation, (iii) control of protein abundance
through ubiquitin-mediated protein degradation by the 26S
proteasome, (iv) control of post-translational modifications of
transcription factors, such as phosphorylation and acetylation, and
(v) control of subcellular localization of transcription factors for its
accessibility to target genes through cytoplasmic-nuclear traffick-
ing. Among these regulatory levels, regulating Nrf2 abundance is a
critical step, which can be achieved by transcription, translation,
and protein stability. Keap1-mediated ubiquitination and protea-
somal degradation of Nrf2 has been proven to be the primary
control in turning on or off the Nrf2 signal. However, multiple
regulatory mechanisms exist in controlling the activity of Nrf2. For
example, phosphorylation of Nrf2 by different kinases was
reported to play a role in controlling Nrf2 activities although
mutagenesis studies have not identified the functional importance
of any phosphorylatable residues [2,25,26,27,28]. Nucleocytoplas-
mic trafficking provides another level of regulation and is essential
for turning off the Nrf2 signaling pathway following oxidative
challenge [29]. Recently, our group has demonstrated that
Nrf2 acetylation at multiple lysine residues located in the Neh1
DNA binding domain is important in fine-tuning the activity of
Nrf2 [30]. Enhanced Nrf2 translation was observed when rat
cardiomyocytes were treated with hydrogen peroxide although the
detailed mechanism of how the Nrf2 translation increased remains
unknown [31]. Enhanced transcription of Nrf2 was reported to
contribute to an increase in Nrf2 protein when murine
keratinocytic cells were challenged with anticarcinogen D3T
[32]. The protein stability of Nrf2 is also controlled by the Neh6
domain of Nrf2 in an Keap1-independent mechanism in stressed
cells [33]. A recent biochemical and genetic study on various Nrf2-
inducing compounds using a zebra fish model demonstrates that
many proteins may be involved in regulating the activity of Nrf2
[18]. Therefore, many proteins may work coordinately with
Keap1 in controlling the activity of Nrf2 and its antioxidant
responses.
BTB-Kelch proteins, containing BTB and Kelch domains at the
amino and carboxyl termini respectively, make up a superfamily in
mammals and invertebrates [34,35]. Bioinformatics studies have
identified over 41 genes in the human genome coding for BTB-
Kelch proteins. While the function(s) of most BTB-Kelch proteins
are unknown, some have been identified to function as substrate
adaptors for the E3 ubiquitin ligase complexes that are required
for ubiquitin-mediated protein degradation [36,37,38,39]. Keap1
is the first BTB-Kelch protein identified to work as a substrate
adaptor in the Cul3-based E3 ubiquitin ligase [19,40,41,42].
Another BTB-Kelch protein KLHL12 was reported to target the
D4 dopamine receptor to the Cul3-dependent E3 ubiquitin ligase
for degradation, which is essential in controlling neurotransmitter
dopamine signaling in the brain [39]. Previous studies have
verified that ENC1 is able to form a functional complex with Cul3-
Rbx proteins, resulting in auto-ubiquitination of ENC1. To clarify
the function of BTB-Kelch proteins, we tested several BTB-Kelch
proteins for their possible roles as substrate adaptor proteins to
regulate Nrf2. Our results demonstrated that ENC1 markedly
down-regulated the protein level of Nrf2 and the transcription of
NQO1 and HO-1, but not the mRNA expression of Nrf2.
Surprisingly, ubiquitination of Nrf2 was not altered in the presence
of ENC1. Pulse-chase analysis showed that ENC1 reduced the rate
of Nrf2 protein synthesis without affecting the stability of Nrf2.
These results provide strong evidence indicating that ENC1 is a
negative regulator of Nrf2.
Materials and Methods
Cell culture and transfection
MDA-MB-231 cells were purchased from ATCC and main-
tained in Eagle’s minimal essential medium (MEM) supplemented
with 10% fetal bovine serum (FBS). Cell cultures were incubated
at 37uC in a humidified incubator containing 5% CO2. Transient
cell transfection was carried out with Lipofectamine Plus
(Invitrogen) according to the manufacturer’s instructions.
Construction of recombinant plasmid DNA
Construction of plasmids expressing wild-type ENC1-Myc,
GAN1-Myc, sarcosin-Myc, HA-Nrf2, Keap1-CBD (chitin binding
domain), HA-Ub (Ubiquitin) and Gal4-Neh2 proteins were
previously described [43]. ENC1 deletion mutants, E320 and
E570, were created by cloning PCR-generated DNA fragments in
a pcDNA3.1 vector. The integrity of all cDNAs used in this study
was confirmed by sequencing.
Antibodies, immunoprecipitation and immunoblot
analysis
Antibodies against Nrf2, Myc, HA, b-Actin, Tubulin, Gal4
(Santa Cruz Biotechnology), and CBD (New England Biolabs)
were purchased from commercial sources. For detection of protein
expression in total cell lysates, cells were washed with phosphate-
buffered salt (PBS) buffer and lysed with sample buffer containing
50 mM Tris-HCl (pH6.8), 2% SDS, 10% glycerol, 100 mM DTT,
0.1% bromophenol blue at 48 hr post-transfection. Immunopre-
cipitation was performed with cell lysates in radio immunopre-
cipitation assay (RIPA) buffer (10 mM sodium phosphate, pH8.0,
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS) containing 1 mM DTT, 1 mM phenylmethylsulfonyl
fluoride, and protease inhibitor mixture (Sigma). Cell lysates were
incubated with 1 mg of antibodies and 10 ml of protein A-agarose
beads at 4uC overnight. Immunoprecipitated complexes were
washed four times with RIPA buffer and eluted in sample buffer
by boiling for 5 minutes. Samples were resolved by SDS-
polyacrylamide gels and transferred onto nitrocellulose mem-
branes for immunoblot analysis.
In vivo Ubiquitination assay
MDA-MB-231 cells were transfected with expression plasmids
for HA-Ub and the indicated proteins. After 48 h, cells were lysed
in a buffer containing 2% SDS, 150 mM NaCl, 10 mM Tris-HCl
and 1 mM DTT. Cell lysates were boiled immediately for
10 minutes to inactivate cellular ubiquitin hydrolases and thus
preserve ubiquitin-protein conjugates. The heated lysates were
cooled down, diluted 5 times with a Tris-buffered salt (TBS)
solution without SDS and used for immunoprecipitation with anti-
Gal4 antibodies. Immunoprecipitated proteins were subjected to
immunoblot analysis with antibodies against HA.
Reporter gene activity assay
Plasmids for mouse GST-ARE-dependent firefly luciferase,
control renilla luciferase (hRluc/TK from Promega), and other
genes were co-transfected into MDA-MB-231 cells, followed by
treatment with indicated chemicals for 16 hr. Cells were lysed at
48 hr posttransfection with passive lysis buffer (Promega) and the
lysates were used to measure firefly and renilla luciferase activities
using the Promega dual-luciferase reporter gene assay system.
ENC1-Nrf2 Negative Regulator
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Total RNA extraction, first-strand cDNA synthesis and PCR
conditions were reported previously [7]. Taqman probes were
from the Roche universe probe library: hNrf2 (#70), hENC1
(#49), hKeap1 (#10), hNQO1 (#87), hHO-1 (#25), hGAPDH
(#25). Oligo DNA primers were synthesized from IDT and the
sequences are shown below.
hNrf2: forward acacggtccacagctcatc, reverse tgtcaatcaaatcca-
tgtcctg;
hENC1: forward ccccacaatcaacaaatgg, reverse actactgcggc-
gttgctaa;
hKeap1: forward attggctgtgtggagttgc, reverse caggttgaagaac-
tcctcttgc;
hNQO1: forward atgtatgacaaaggacccttcc, reverse tcccttgcaga-
gagtacatgg;
hHO-1: forward aactttcagaagggccaggt, reverse ctgggc-
tctccttgttgc;
hGAPDH: forward ctgacttcaacagcgacacc, reverse tgctgtagc-
caaattcgttgt.
All data were obtained from triplicate samples and presented as
fold changes of mRNA levels, compared with the indicated
controls in the graph.
Pulse-chase analysis
Following incubation of MDA-MB-231 cells for 15 min in
DMEM medium lacking methionine, cysteine and L-glutamine
(Sigma), complemented with 10% dialyzed FBS, cells were
cultured for 30 min in labeling medium containing 0.3 mCi/ml
[
35S]-methionine and [
35S]-cysteine to label proteins. Cells were
washed once with complete medium and cultured in complete
medium at 37uC for the indicated chase time periods before cell
lysis. Nrf2-containing pretein complexes were immunoprecipitated
with anti-Nrf2 antibodies in RIPA buffer. Immunoprecipitated
proteins were subjected to SDS-PAGE gel resolution and
autoradiography.
Results
Nrf2 was down-regulated by ENC1
Bioinformatic analysis identified about 41 genes in the human
genome that encode BTB-Kelch domain-containing proteins
[34,35]. It has been reported that each of the BTB-Kelch
proteins, such as Keap1, ENC1, GAN1 or sarcosin, can function
as a substrate adaptor by forming a complex with Cul3-Rbx 1 and
is active in targeting self-ubiquitination of BTB-Kelch proteins
[43]. To further investigate the possible effect of ENC1, GAN1 or
sarcosin on Nrf2, MDA-MB-231 cells were transiently transfected
with expression vectors for HA-Nrf2 and either ENC1-Myc,
GAN1-Myc or sarcosin-Myc, and were subjected to immunoblot
analysis. Keap1-CBD was included as a positive control.
Interestingly, ENC1 and GAN1 reduced the protein level of
Nrf2, although to a lesser degree, compared to Keap1 (Fig. 1A,
compare lanes 2–4 with lane 1). In contrast, sarcosin had no effect
(Fig. 1A, compare lane 5 with lane 1). In order to demonstrate that
the ENC1-mediated down-regulation of Nrf2 is not due to an
artifact from the expression vector, but rather specific in down-
regulating Nrf2, a similar experiment was performed using HA-
tagged survival motor neuron (HA-SMN) in place of HA-Nrf2.
HA-SMN cDNA was cloned into the same cloning site using the
same expression vector as HA-Nrf2. SMN is a gene correlated
with loss of function of motor neurons of the spinal cord [44]. In
contrast to HA-Nrf2, the level of HA-SMN was not reduced by
overexpression of ENC1 (Fig. 1B, lane 3 and 4). Effects of ENC1
on endogenous Nrf2 were also examined in MDA-MB-231 cells
transfected with ENC1-Myc alone. Nrf2 inducer tert-butylhydro-
quinone (tBHQ) was added to half of the samples for 4 hrs before
cells were harvested to enhance Nrf2 levels. Cell lysates were
subjected to immunoblot with anti-Nrf2 antibodies (Fig. 1C, left
panel) and the Nrf2 band intensities were quantified and plotted
(Fig. 1C, right panel). ENC1-mediated down-regulation of
endogenous Nrf2 was observed in both untreated and tBHQ-
treated samples (Fig. 1C, both left and right panels). To further
confirm that ENC1 down-regulates Nrf2 specifically, cells were
transfected with different amounts of an ENC1 expression vector,
along with an expression vector for HA-Nrf2, and cell lysates were
subjected to immunoblot analysis. ENC1 was able to down-
regulate Nrf2 in a dose-dependent manner (Fig. 1D). Furthermore,
overexpression of ENC1 did not elicit an unfolded protein
response (UPR) as demonstrated by the same expression level of
Derlin-1, an protein that is upregulated in response to UPR,
among the samples (Fig. 1D). Collectively, these results demon-
strated that ENC1 is able to down-regulate Nrf2 specifically.
ENC1 down-regulated Nrf2 at the posttranscriptional
level
Next, the effect of ENC1 on the transcriptional activity of
Nrf2 was tested in the absence or presence of Nrf2 inducers.
MDA-MB-231 cells were transfected with expression vectors for
NQO1-ARE-luciferease reporter gene and HA-Nrf2, along with
an expression vector for ENC1 or Keap1. Renilla luciferase
reporter gene was used as an internal control. tBHQ or SF
activated the transcriptional activity of endogenous Nrf2, demon-
strating that the reporter gene system is functional (Fig. 2A).
Similar to Keap1, ENC1 decreased transcriptional activities of
Nrf2 in both untreated and treated conditions (Fig. 2A). Small
aliquots of the same cell lysates were used for immunoblot analysis
(Fig. 2B, both left and right panels). In agreement with the
transcriptional activity of Nrf2, overexpression of ENC1 resulted
in a decease in the Nrf2 protein level in both untreated and treated
conditions (Fig. 2B, right panel, compare lanes 5–7 with lanes 2–
4), indicating that ENC1 down-regulates the activity of Nrf2,
primarily though reducing the protein level of Nrf2. However, the
reduction of the transcriptional activity and the protein level of
Nrf2 by ENC1 was not as substantial as that by Keap1 (Fig. 2A;
Fig. 2B, right panel, compare lane 5 with lane 8), indicating that
Keap1 is the primary regulator of the Nrf2-dependent cellular
antioxidant response.
To explore the regulatory mechanism by which ENC1 down-
regulates Nrf2, the mRNA levels of Nrf2 and two of its
downstream target genes were determined using quantitative
real-time RT-PCR in cells transfected with an expression vector
for ENC1-Myc or Keap1 in the absence or presence of tBHQ.
Similar to Keap1, ENC1 did not change Nrf2 mRNA expression
in both treated and untreated conditions (Fig. 2C, Nrf2 panel).
Under basal conditions, neither ENC1 nor Keap1 showed effects
on mRNA expression of NQO1 and HO-1 (Fig. 2C, NQO1 and
HO-1 panels), this is likely due to the low constitutive amount of
Nrf2 and transcription of its downstream genes in this cell line.
However, ectopic expression of ENC1 significantly decreased
mRNA expression of NQO1 or HO-1 in cells treated with tBHQ
(Fig. 2C, NQO1 and HO-1 panels, compare bar 4 with bar 3).
Overexpression of ENC1 and Keap1 were confirmed by a robust
induction of ENC1 and Keap1 mRNA (Fig. 2C, ENC1 and
Keap1 panels). Taken together, these results demonstrate that
ENC1 is able to suppress Nrf2 and its target gene expression
without affecting Nrf2 mRNA levels. Thus, ENC1 down-regulates
Nrf2 at the protein level, not at the transcriptional level.
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PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5492Figure 1. ENC1 down-regulated Nrf2. A. MDA-MB-231 cells were transfected with an expression vector for HA-Nrf2, along with an empty vector
or a plasmid for ENC1-Myc, Keap1-CBD, GAN1-Myc or Sarcosin-Myc. Transfected cells were lysed at 48 hr post-transfection and cell lysates were
subjected to immunoblot analysis with anti-HA, anti-Myc, anti-CBD and anti-tubulin antibodies. B. An expression vector for HA-Nrf2 or HA-SMN gene
was transfected into MDA-MB-231 cells, along with an empty vector or an expression vector for ENC1-Myc. Cells were harvested and immunoblot
analysis was performed. C. An expression vector for ENC1-Myc was transfected into MDA-MB-231 cells. Cells were left untreated or treated with
50 mM tBHQ for 16 hr before cell lysis. Cell lysates were subjected to immunoblot analysis (left panel). The intensities of the Nrf2 bands were
quantified by the ChemiDoc XRS gel documentation system and Quantity One software from Bio-Rad (right panel). D. MDA-MB-231 cells were
transfected with different amounts of an ENC1-Myc expression vector, along with an expression vector for HA-Nrf2. Cell lysates were subjected to
immunoblot analysis with anti-HA and anti-Derlin-1 antibodies.
doi:10.1371/journal.pone.0005492.g001
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ubiquitin-mediated proteasomal degradation
mechanism
It has been well-established that Keap1 down-regulates Nrf2
through a ubiquitin-mediated proteasomal degradation machinery
by functioning as a substrate adaptor for the Keap1-Cul3-Rbx1 E3
ubiquitin ligase. Suppression of Nrf2 by ENC1 is reminiscent of
down-regulation of Nrf2 by Keap1. Since ENC1 has been shown to
form a complex with Cul3-Rbx1 and may also function as a
substrate adaptor, it is possible that Nrf2 may also be a substrate for
the ENC1-Cul3-Rbx1 E3 ubiquitin ligase. Therefore the interaction
between Nrf2 and ENC1 was determined by immunoprecipitation
analysis with ectopically expressed HA-Nrf2 and ENC1-Myc.
However, no interaction between these two proteins, even as
overexpressed proteins, was detected (data not shown).
If the ENC1-mediated down-regulation of Nrf2 is through
proteasomal degradation of Nrf2, then proteasomal inhibitors
should be able to block the degradation of Nrf2 when ENC1 is
overexpressed. Therefore, three proteasomal inhibitors, MG132,
clasto-lactacystin b-lactone and epoxomicin, were tested for their
ability to suppress the ENC1-induced decrease in Nrf2 expression.
MG132 treatment resulted in a significant induction of endoge-
nous Nrf2 in MDA-MB 231 cells (Fig. 3A, compare lane 1 with
lane 2). However, the fold of induction by MG132 in mock-
transfected MDA-MB 231 cells is equivalent to that in ENC1-
Figure 2. ENC1 down-regulated Nrf2 at the posttranscriptional level. A. MDA-MB-231 cells transfected with plasmids for ARE-driven firefly
luciferase, TK-renilla luciferase and the indicated genes were treated with 7.5 mMS Fo r5 0mM tBHQ for 16 hr prior to cell lysis. Firefly and renilla
luciferase activities were measured. Means and standard deviations were calculated from three independent experiments. B. Small aliquots of the
lysates were subjected to immunoblot analysis with anti-Nrf2 (left panel), anti-HA, anti-Myc, anti-CBD and anti-b-actin antibodies (right panel). C. An
empty plasmid or a plasmid for either ENC1-Myc or Keap1 was transfected into MDA-MB-231 cells and cells were treated with tBHQ for 16 hr. At 48 hr
post-transfection, the relative mRNA levels of Nrf2, NQO1, HO-1, ENC1 and Keap1 were determined by real-time PCR.
doi:10.1371/journal.pone.0005492.g002
Figure 3. ENC1-mediated down-regulation of Nrf2 was independent of proteasomal or lysosomal degradation. A. MDA-MB-231 cells
were transfected with an empty vector or a vector for ENC1-Myc. Transfected cells were treated with proteasome inhibitors MG132 (M) (10 mM),
clasto-lactacystin b-lactone (Lac) (10 mM) or epoxomicin (Ep) (1 mM), or lysosome inhibitors chloroquine (Ch) (50 mM) or ammonium chloride (Ac)
(50 mM) for 4 hr before cells were lysed at 48 hr post-transfection. Cell lysates were subjected to immunoblot analysis with anti-HA, anti-Myc and
anti-b-actin antibodies. B. MDA-MB-231 cells were transfected with HA-Nrf2 and with an empty vector or ENC1-Myc. Transfected cells were treated
with proteasome and lysosome inhibitors as described above. Immunoblot analysis was performed. C. In vivo ubiquitination assay was performed in
MDA-MB-231 cells transfected with plasmids for HA-Ub and Gal4-Neh2, along with either ENC1-Myc or Keap1-CBD. Transfected cells were treated
with 10 mM MG132 for 4 hr prior to cell lysis. Cell lysates were denatured by heating and subjected to immunoprecipitation with anti-Gal4 antibodies.
The precipitated protein complexes were subjected to immunoblot analysis with anti-HA antibodies for detecting ubiquitin-conjugated Gal4-Neh2
(top panel). Small aliquots of total cell lysates were immunoblotted with the indicated antibodies (bottom three panels).
doi:10.1371/journal.pone.0005492.g003
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5492Figure 4. Keap1 was not essential in ENC1-mediated down-regulation of Nrf2. A. MDA-MB-231 cells were transfected with an expression
vector for ENC1-Myc, along with an empty vector or an expression vector for Keap1-CBD. Cell lysates were subjected to chitin pull-down assay.
Precipitated proteins were subjected to immunoblot analysis with anti-Myc and anti-CBD antibodies for detection of Keap1-CBD and ENC1-Myc (top
panel). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (bottom panel). B. Cell lysates from MDA-MB-231
cells were immunoprecipitated with anti-Keap1 antibody. The precipitated protein complexes were subjected to immunoblot analysis with anti-Nrf2
ENC1-Nrf2 Negative Regulator
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with lanes 1 and 2). Similar levels of induction were observed when
clasto-lactacystin b-lactone or epoxomicin was used (Fig. 3A,
compare lanes 5 and 6 with lane 4). These results indicate that
induction of Nrf2 in response to MG132 is due to blockage of
Keap1-dependent proteasomal degradation of Nrf2 and ENC1-
mediated down-regulation is unlikely through proteasomal
degradation. Lysosome inhibitors, ammonium chloride and
chloroquine, did not change Nrf2 levels (Fig. 3A, lanes 7, 8 and
3). These results clearly demonstrate that the ENC1-mediated
down-regulation of Nrf2 is independent of proteasomal and
lysosomal degradation machinery.
To further test this notion, a similar experiment was performed
with overexpressed HA-Nrf2 to saturate endogenous Keap1, and
therefore minimize the effect of Keap1 on Nrf2. MDA-MB-231
cells transfected with HA-Nrf2 and ENC1-Myc were treated with
proteasomal and lysosomal inhibitors and the cell lysates were
subjected to immunoblot analysis. Overexpression of ENC1
significantly reduced Nrf2 (Fig. 3B, compare lane 1 with lane 3).
As expected, none of the inhibitors was able to restore the level of
Nrf2 in ENC1-overexpressed cells (Fig. 3B, compare lane 4–8 with
lane 3), indicating that the recovery of endogenous Nrf2 following
proteasomal inhibition is solely due to blockage of the Keap1-
mediated Nrf2 degradation (Fig. 3A, compare lanes 4–6 with lane
3). Taken together, these results show that neither the proteasome
nor lysosome plays a role in the ENC1-mediated down-regulation
of Nrf2.
Subsequently, a ubiquitination assay was performed to further
prove that Nrf2 down-regulation by ENC1 is independent of the
ubiquitin-mediated proteasomal degradation machinery. Overex-
pression of ENC1 did not increase ubiquitination of the
transfected Neh2 domain of Nrf2 while Keap1 enhanced Neh2
ubiquitination significantly (Fig. 3C). This result shows that unlike
Keap1, ENC1 does not participate in ubiquitination of Nrf2 and
thus its down-regulation of Nrf2 is independent of ubiquitination
and proteasomal degradation.
Down-regulation of Nrf2 by ENC1 was independent of
Keap1-ENC1 interaction
To explore the mechanism of ENC1-mediated down-regulation
of Nrf2, interaction of ENC1 with Keap1 was examined. Chitin
pull-down assay was performed with transiently expressed Keap1-
CBD and ENC1-Myc. Clearly, both Keap1-CDB and ENC1-Myc
were present in CBD-bound complexes (Fig. 4A). Next, immuno-
precipitation of endogenous Keap1 and ENC1 was performed
with anti-Keap1 antibodies and Keap1 immunoprecipitates were
subjected to immunoblot with anti-ENC antibodies. Immunoblot
with anti-Nrf2 antibodies was also performed for this experiment
as a positive control. Keap1 immunoprecipitates contained both
Nrf2 and ENC1 (Fig. 4B, bottom and top panels). This
encouraged us to test the direct interaction between ENC1 and
Keap1. E.coli-expressed His-tagged Keap1 was incubated with
ENC1 wild-type and two ENC1 deletion mutants that were
synthesized in vitro in the presence of [
35S]-methionine. Nickel
beads were used to pull-down the Keap1-containing complexes.
[
35S]-labeled luciferase and Nrf2 were included as a negative and
positive control. The results showed that ENC1 wild-type and the
deletion mutants were not precipitated by Keap1-His (Fig. 4C),
indicating that the association between Keap1 and ENC1 is
indirect.
Since there was an indirect interaction between Keap1 and
ENC1, the possible involvement of Keap1 in ENC1-mediated
down-regulation of Nrf2 was examined. Keap1 wild-type and
knockout mouse embryonic fibroblast (MEF) cells were transfected
with HA-Nrf2 and ENC1-Myc to check if there is a difference
in the ENC1-mediated Nrf2 down-regulation between wild-type
and knockout cells. Overexpression of ENC1 was able to suppress
the level of Nrf2 to a similar degree in both cell lines (Fig. 4D,
left and right panels). This result suggests that Keap1 is not
involved in ENC1-mediated down-regulation of Nrf2. The
influence of ENC1 on the binding affinity between Keap1 and
Nrf2 was also examined using chitin pull-down assay to
characterize if ENC1 and Nrf2 compete with each other for
Keap1 binding. Total Nrf2 level was reduced by Keap1 and
was further decreased by ENC1 (Fig. 4E, left figure, lower
panel, lanes 2 and 3). After pull-down with Keap1-CBD, the
ratio of precipitated Nrf2 levels in the presence and absence of
ENC1 (Fig. 4E, left figure, top panel, lanes 2 and 3) was
comparable with that in total lysates (Fig. 4E, left figure,
lower panel, lanes 2 and 3; right graphic). These results show
that ENC1 does not influence the binding affinity of Nrf2 and
Keap1 and that the ENC1-mediated down-regulation of Nrf2 is
independent of the indirect interaction between Keap1 and
ENC1.
ENC1 down-regulated Nrf2 by decreasing the rate of Nrf2
protein synthesis
The data show that reduction of Nrf2 by ENC1 was
independent of proteasomal or lysosomal-dependent degradation.
Furthermore, results from real-time PCR demonstrate that
overexpression of ENC1 did not affect the mRNA level of Nrf2.
Thus, it is most likely that Nrf2 modulation by ENC1 is at the level
of protein synthesis. To test this, pulse-chase analysis was carried
out in two sets of samples: vector-transfected or ENC1-Myc-
transfected MDA-MB-231 cells were either left untreated or
treated with tBHQ. Newly synthesized proteins were radio-labeled
by incubating cells with medium containing [
35S]-methionine and
[
35S]-cysteine for 30 minutes, and the cells were lysed at the
indicated time points and subjected to immunoprecipitation using
anti-Nrf2 antibodies. Immunoprecipitated Nrf2 proteins were
resolved in SDS-PAGE gel. Results of autoradiographic analysis
show that newly synthesized Nrf2 within a 30 minute-pulse time
period was decreased in cells transfected with ENC1, compared to
that in vector-transfected cells in both untreated and treated
groups (Fig. 5A and 5C, compare first lanes, labeled 0 minute).
Further, pulse-chase analysis also indicates that there was no
and anti-ENC1 antibodies. IgG was included in the immunoprecipitation analysis as a negative control. C. Plasmids for full-length ENC1 (E-FL) and two
ENC1 deletion mutants E320 and E570, Nrf2 and Luciferase (Luc) were used for in vitro transcription/translation to synthesize [
35S]-labeled proteins.
The proteins were incubated with Keap1-His purified from E. Coli. Protein complexes containing Keap1 were pulled-down with nickel beads and
resolved in SDS-PAGE and detected by autoradiography. Nrf2 and Luciferase were used as a positive and a negative control. 20% of [
35S]-labeled
proteins were resolved by SDS-PAGE gel to show equivalent input of each protein (right panel). D. Keap1-/- and wild-type MEF cells were transfected
with plasmids for HA-Nrf2 and ENC1-Myc. Cells were lysed at 48 hr post-transfection. Cell lysates were analyzed by immunoblot with anti-HA, anti-
Myc and anti-b-actin. E. Cell lysates from MDA-MB-231 cells transfected with plasmids for Keap1-CBD, HA-Nrf2, and ENC1-Myc were used for pull-
down assay with chitin beads Precipitated proteins were subjected to immunoblot analysis with anti-HA and anti-CBD antibodies (left figure, top two
panels). Small aliquots of total lysates were analyzed by immunoblot with the indicated antibodies (left figure, bottom four panels). Nrf2 and b-Actin
band intensities were quantified using Quantity One (BIO-RAD). The intensity of Nrf2 was normalized to that of b-actin (right graph).
doi:10.1371/journal.pone.0005492.g004
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5492Figure 5. ENC1 down-regulated Nrf2 at the translational level. A. Pulse-chase assay was conducted with MDA-MB-231 cells transfected with
either an empty vector or an expression vector for ENC1-Myc. Cells were incubated for 30 minutes with medium containing [
35S]-methionine and
[
35S]-cysteine to label proteins. Cells were then washed and incubated in normal complete medium for the indicated time periods prior to cell lysis.
Cell lysates were subjected to immunoprecipitation with anti-Nrf2 antibodies and immunoprecipitates were resolved in SDS-PAGE gel and detected
by autoradiography. B. Nrf2 band intensities were quantified using Quantity One (BIO-RAD) and the half-life was plotted and calculated. C. Pulse-
chase assay was conducted in the same way, except that cells were treated with 100 mM tBHQ for 4 hr. D. Quantified data of Fig. 5C.
doi:10.1371/journal.pone.0005492.g005
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and 5D). Together, these results demonstrate that ENC1-mediated
Nrf2 down-regulation is not through protein degradation, but
rather through suppressing Nrf2 protein synthesis.
Discussion
ENC1 and Keap1 both belong to the BTB-Kelch family and
resemble each other in sequence and domain organization,
indicating that ENC1 may have a similar role as Keap1 [43].
One of the major functions of Keap1 is as a substrate adaptor
protein to target Nrf2 to the Cul3-based E3 ubiquitin ligase for
ubiquitination and subsequent degradation by the 26S protea-
some. Although few BTB-Kelch proteins have been demonstrated
to function as a substrate adaptor for a E3 ubiquitin ligase, BTB-
Kelch proteins have been demonstrated to have other functions
not related to being substrate adaptors of E3 ubiquitin ligases. For
example, the neuronal protein KRIP6, a BTB-Kelch protein,
regulates the plasma membrane kainate receptor GluR6-mediated
current in neurons through two different mechanisms [45]. One is
modulating the association of GluR6 with the PDZ domain-
containing protein, PICK1. Another mechanism relies on its direct
binding with GluR6. Our study demonstrates that although ENC1
is able to down-regulate the protein level of Nrf2 and its
downstream effects, its inhibitory function is independent of the
ubiquitin-dependent proteasomal degradation pathway. The
ENC1-mediated down-regulation of Nrf2 is accomplished through
suppressing the rate of Nrf2 protein synthesis. Our results
demonstrate that individual member of the BTB-Kelch family
may have different functions and can regulate diverse cellular
functions. Currently, how ENC1 is able to suppress the Nrf2
protein synthesis is unclear and further investigation is needed.
ENC1, also named NRP/B, is a nuclear matrix protein [46]. It
is primarily expressed in the nervous system and has been
demonstrated to be up-regulated during neuronal differentiation
and is important for the differentiation process by interacting with
active hypophosporylated p110 (RB) [46,47]. In addition to
regulating neuronal differentiation, ENC1 was also reported to be
functionally important in regulating differentiation processes in
adipocytes [48]. Disregulation of ENC1, such as mutation,
overexpression, and mis-localization, was believed to contribute
to brain tumorigenesis by enhancing cell proliferation, and
inhibiting apoptosis [49,50]. In tumor cells purified from patients
suffering from hairy cell leukemia, ENC1 was significantly
overexpressed in all the samples [51]. Interestingly, the cellular
localization of ENC1 is controversial. Both nuclear and cytoplas-
mic localization has been reported. Nuclear localization of ENC1
is consistent with ENC1 being a nuclear matrix protein. However,
ENC1 is also a member of BTB-Kelch family that interacts with
actin through the Kelch domain and thus colocalizes with actin in
the cytosol. We have detected cytoplasmic localization of four
BTB-Kelch proteins, Keap1, ENC1, GAN-1, and sarcosin (data
not shown).
Contradictory to our results demonstrating a negative effect of
ENC1 on Nrf2 and its downstream genes, Avraham’s group
reported that ENC1 interacts with Nrf2 and upregulates NQO1
expression [52,53]. The ENC1 cDNA used in our study encodes
the exactly same amino acid sequence as the one used by
Avraham’s group. The discrepancy is unlikely due to the cell types
used since same cell lines such as MDA-MB-231, COS and SH-
SY5Y were used in the experiments (Our data with COS and SH-
SY5Y cells were not shown). Ectopically expressed ENC1 wild-
type was localized in the cytosol in our experimental settings,
which is consistent with a report showing colocalization of ENC1
with actin filaments [48]. However, ectopically expressed ENC1
was detected exclusively in the nucleus in the studies from
Avraham’s group [52,53]. In addition, we failed to detect
interaction of ENC1 and Nrf2 in many cell types tested, although
ENC1 interacts with Keap1 weakly and indirectly. It is most likely
that the divergent results are due to the fact that we tagged Myc at
the C-terminus of ENC1 while they used N-terminal Myc-tagged
ENC1.
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